Related Experiment Video

Updated: Jul 15, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Anti-angiogenic therapy in renal cell cancer

Ramaprasad Srinivasan1, Andrew J Armstrong, William Dahut

  • 1Urologic Oncology Branch, Center for Cancer Research, Division of Cancer Prevention, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.

BJU International
|April 20, 2007
PubMed

Insights

Angiogenesis is key in renal cell carcinoma (RCC). While targeting vascular endothelial growth factor (VEGF) shows promise, further research is needed to optimize anti-angiogenic therapies for advanced RCC.

Area of Science:

  • Oncology
  • Neovascularization Biology
  • Renal Cell Carcinoma (RCC) Therapeutics

Background:

  • Angiogenesis, the formation of new blood vessels, is a critical characteristic of renal cell carcinoma (RCC).
  • Vascular Endothelial Growth Factor (VEGF) is a key pro-angiogenic factor and a validated therapeutic target in RCC.
  • Multi-targeted tyrosine kinase inhibitors (TKIs) inhibiting VEGFRs are FDA-approved for advanced RCC treatment.

Purpose of the Study:

  • To evaluate the role of anti-angiogenic strategies in renal cell carcinoma (RCC).
  • To explore the potential of combining different anti-angiogenic agents for enhanced efficacy in RCC.
  • To determine the extent to which clinical benefits of anti-angiogenic strategies in RCC can be further improved.

Main Methods:

  • Review of existing studies on angiogenesis in RCC.
  • Analysis of clinical benefits of approved anti-angiogenic therapies, including multi-targeted TKIs.
  • Examination of ongoing studies combining VEGFR-targeted strategies with other anti-angiogenic agents (e.g., anti-VEGF antibodies, IFN, mTOR inhibitors).

Main Results:

  • VEGF-targeted therapies have demonstrated significant clinical benefit in advanced RCC.
  • Pharmacodynamic studies suggest TKIs possess anti-angiogenic effects beyond VEGFR inhibition.
  • Combinatorial approaches involving VEGFR inhibitors and other anti-angiogenic agents are under investigation.

Conclusions:

  • Anti-angiogenic strategies, particularly targeting VEGF, are established treatments for advanced RCC.
  • The combination of VEGFR-targeted therapies with other anti-angiogenic agents is a promising area of research.
  • Further investigation is required to fully understand and maximize the clinical benefit of advanced anti-angiogenic strategies in RCC.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Imaging Studies VII: Vascular Imaging01:19

Imaging Studies VII: Vascular Imaging

DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.